PL4313967T3 - Inhibitory khk - Google Patents
Inhibitory khkInfo
- Publication number
- PL4313967T3 PL4313967T3 PL22719399.2T PL22719399T PL4313967T3 PL 4313967 T3 PL4313967 T3 PL 4313967T3 PL 22719399 T PL22719399 T PL 22719399T PL 4313967 T3 PL4313967 T3 PL 4313967T3
- Authority
- PL
- Poland
- Prior art keywords
- khk
- inhibitors
- khk inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163167331P | 2021-03-29 | 2021-03-29 | |
| PCT/US2022/021912 WO2022212194A1 (en) | 2021-03-29 | 2022-03-25 | Khk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4313967T3 true PL4313967T3 (pl) | 2026-04-20 |
Family
ID=81388962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22719399.2T PL4313967T3 (pl) | 2021-03-29 | 2022-03-25 | Inhibitory khk |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12410160B2 (https=) |
| EP (2) | EP4681774A3 (https=) |
| JP (2) | JP7705475B2 (https=) |
| KR (1) | KR20230158542A (https=) |
| CN (1) | CN117120429A (https=) |
| AR (1) | AR125238A1 (https=) |
| AU (2) | AU2022252182B2 (https=) |
| CA (1) | CA3214961A1 (https=) |
| ES (1) | ES3061522T3 (https=) |
| PL (1) | PL4313967T3 (https=) |
| TW (2) | TW202448875A (https=) |
| WO (1) | WO2022212194A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230098069A (ko) * | 2021-12-24 | 2023-07-03 | 주식회사 엘지화학 | (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물 |
| CN119923397A (zh) * | 2022-10-24 | 2025-05-02 | 柳韩洋行 | 用于制备二甲基-2,3-二氢-1h-茚衍生物的改进方法 |
| WO2024125482A1 (zh) * | 2022-12-13 | 2024-06-20 | 华领医药技术（上海）有限公司 | 作为己酮糖激酶抑制剂的化合物、其用途以及包含其的组合物 |
| WO2025184056A1 (en) * | 2024-02-26 | 2025-09-04 | Miralogx Llc | Synthetic cannabinoid analogs, pharmaceutical compositions and methods of treating anxiety and other disorders |
| WO2025250674A1 (en) * | 2024-05-30 | 2025-12-04 | Miralogx Llc | Synthetic cannabinoid analogs, pharmaceutical compositions and methods of treating neurological disorders and other conditions |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041443A (en) * | 1989-02-21 | 1991-08-20 | Dainippon Pharmaceutical Co., Ltd. | Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof |
| US5137890A (en) | 1990-02-14 | 1992-08-11 | Ortho Pharmaceutical Corporation | 4-phenyl tetrahydropyrido(4,3-d)pyrimidines |
| GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| DE602004014347D1 (de) * | 2003-03-12 | 2008-07-24 | Millennium Pharm Inc | Chinazolin-derivate als tgf-beta-inhibitoren |
| JP2007510642A (ja) * | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| WO2007019083A1 (en) | 2005-08-04 | 2007-02-15 | Janssen Pharmaceutica N.V. | Pyrimidine compounds as serotonin receptor modulators |
| US7851468B2 (en) * | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
| WO2009045174A1 (en) * | 2007-10-05 | 2009-04-09 | S*Bio Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| WO2010053825A1 (en) | 2008-10-29 | 2010-05-14 | Janssen Pharmaceutica Nv | 2-aminopyrimidine compounds as serotonin receptor modulators |
| AU2009314544C1 (en) * | 2008-11-11 | 2015-11-12 | Xcovery Holding Company Llc | PI3K/mTOR kinase inhibitors |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| US8822447B2 (en) | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| RS57157B1 (sr) | 2011-11-11 | 2018-07-31 | Gilead Apollo Llc | Acc inhibitori i njihove primene |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| US9499561B2 (en) * | 2012-04-10 | 2016-11-22 | Shanghai Yingli Pharmaceutical Co., Ltd. | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof |
| MX2017003933A (es) | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| CN112225699B (zh) | 2014-12-23 | 2023-11-14 | 吉利德科学公司 | 制备ask1抑制剂的方法 |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| EA201791258A1 (ru) | 2015-01-09 | 2017-12-29 | Джилид Аполло, Ллс | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени |
| WO2017027611A2 (en) * | 2015-08-10 | 2017-02-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Biomarkers of methylglyoxal and related methods thereof |
| SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
| SG11201807077RA (en) | 2016-03-02 | 2018-09-27 | Gilead Apollo Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| CN110382503B (zh) | 2017-03-03 | 2022-07-19 | 吉利德科学公司 | 制备acc抑制剂及其固体形式的方法 |
| CA3056890A1 (en) | 2017-03-17 | 2018-09-20 | Regents Of The University Of Colorado, A Body Corporate | Indazole inhibitors of fructokinase (khk) and methods of use in treating khk-mediated disorders or diseases |
| JP2020512342A (ja) | 2017-03-28 | 2020-04-23 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置する方法 |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| JP2020516627A (ja) | 2017-04-12 | 2020-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置する方法 |
| US10980810B2 (en) | 2017-10-06 | 2021-04-20 | Gilead Sciences, Inc. | Combination therapy comprising an ACC inhibitor |
| US12161621B2 (en) | 2018-07-16 | 2024-12-10 | The Regents Of The University Of Colorado | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease |
| TWI714231B (zh) | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| KR102558308B1 (ko) | 2018-09-27 | 2023-07-24 | 주식회사 엘지화학 | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 |
| CN113412260B (zh) | 2019-01-29 | 2022-08-02 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| WO2020185685A1 (en) | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating acne |
| WO2020215022A1 (en) | 2019-04-17 | 2020-10-22 | Colorado Research Partners, Llc | Novel compounds and methods of use treating fructose-related disorders or diseases |
| CN111978296A (zh) | 2019-05-22 | 2020-11-24 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| TWI750685B (zh) * | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| CN114846009B (zh) * | 2019-12-24 | 2023-12-12 | 杭州中美华东制药有限公司 | 具有khk抑制作用的化合物 |
| CN114846008B (zh) | 2019-12-25 | 2024-05-28 | 杭州中美华东制药有限公司 | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 |
| WO2021162943A1 (en) | 2020-02-13 | 2021-08-19 | Eli Lilly And Company | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds |
| CN111423420A (zh) | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| CN114181198B (zh) | 2020-09-15 | 2025-07-15 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类己酮糖激酶抑制剂及其用途 |
| JP2024501507A (ja) * | 2020-12-25 | 2024-01-12 | スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド | ケトヘキソキナーゼ阻害剤及びその用途 |
| CN114805312A (zh) | 2021-01-29 | 2022-07-29 | 上海拓界生物医药科技有限公司 | 一种己酮糖激酶抑制剂及其制备方法 |
| CN114989143A (zh) | 2021-03-02 | 2022-09-02 | 山东轩竹医药科技有限公司 | 并环类己酮糖激酶抑制剂及其用途 |
| WO2022211595A1 (ko) | 2021-04-01 | 2022-10-06 | 주식회사 엘지화학 | 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물 |
-
2022
- 2022-03-25 EP EP25206447.2A patent/EP4681774A3/en active Pending
- 2022-03-25 EP EP22719399.2A patent/EP4313967B1/en active Active
- 2022-03-25 KR KR1020237035032A patent/KR20230158542A/ko active Pending
- 2022-03-25 WO PCT/US2022/021912 patent/WO2022212194A1/en not_active Ceased
- 2022-03-25 CA CA3214961A patent/CA3214961A1/en active Pending
- 2022-03-25 JP JP2023560087A patent/JP7705475B2/ja active Active
- 2022-03-25 ES ES22719399T patent/ES3061522T3/es active Active
- 2022-03-25 CN CN202280024429.7A patent/CN117120429A/zh active Pending
- 2022-03-25 PL PL22719399.2T patent/PL4313967T3/pl unknown
- 2022-03-25 AU AU2022252182A patent/AU2022252182B2/en active Active
- 2022-03-25 US US17/704,440 patent/US12410160B2/en active Active
- 2022-03-28 TW TW113132589A patent/TW202448875A/zh unknown
- 2022-03-28 TW TW111111557A patent/TWI855308B/zh active
- 2022-03-29 AR ARP220100751A patent/AR125238A1/es not_active Application Discontinuation
-
2024
- 2024-12-04 JP JP2024211090A patent/JP7778900B2/ja active Active
-
2025
- 2025-05-19 AU AU2025203602A patent/AU2025203602A1/en active Pending
- 2025-08-22 US US19/307,911 patent/US20260092053A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202246253A (zh) | 2022-12-01 |
| AU2022252182A1 (en) | 2023-09-28 |
| JP7705475B2 (ja) | 2025-07-09 |
| US12410160B2 (en) | 2025-09-09 |
| EP4681774A2 (en) | 2026-01-21 |
| US20260092053A1 (en) | 2026-04-02 |
| AU2022252182B2 (en) | 2025-02-20 |
| EP4313967B1 (en) | 2025-11-12 |
| AR125238A1 (es) | 2023-06-28 |
| TW202448875A (zh) | 2024-12-16 |
| ES3061522T3 (en) | 2026-04-06 |
| EP4681774A3 (en) | 2026-03-25 |
| KR20230158542A (ko) | 2023-11-20 |
| EP4313967A1 (en) | 2024-02-07 |
| JP7778900B2 (ja) | 2025-12-02 |
| US20230079863A1 (en) | 2023-03-16 |
| JP2024512646A (ja) | 2024-03-19 |
| TWI855308B (zh) | 2024-09-11 |
| WO2022212194A1 (en) | 2022-10-06 |
| CN117120429A (zh) | 2023-11-24 |
| CA3214961A1 (en) | 2022-10-06 |
| EP4313967C0 (en) | 2025-11-12 |
| JP2025032196A (ja) | 2025-03-11 |
| AU2025203602A1 (en) | 2025-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL313281B1 (en) | Prmt5 inhibitors that cooperate with mta | |
| SG11202106520VA (en) | Kif18a inhibitors | |
| ZA202109573B (en) | Prmt5 inhibitors | |
| IL276813A (en) | Arginase inhibitors | |
| PL4313967T3 (pl) | Inhibitory khk | |
| ZA202107835B (en) | Prc2 inhibitors | |
| IL277778A (en) | BCL6 inhibitors | |
| ZA202106284B (en) | Rad51 inhibitors | |
| IL314049A (en) | PARP7 inhibitors | |
| IL283112A (en) | LOX inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL276439A (en) | Ghrelin o-acyltransferase inhibitors | |
| GB201809295D0 (en) | Lox inhibitors | |
| IL291368A (en) | Inhibits expression of methadherin | |
| HK40107709A (en) | Khk inhibitors | |
| EP4263533C0 (en) | Erap inhibitors | |
| IL313756A (en) | Inhibitors of the sestrin-MAPK complex | |
| IL320219A (en) | Inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB202015919D0 (en) | Cupa III | |
| IL273122A (en) | Medkations for sevaval illnassess | |
| GB202003422D0 (en) | Disclosure | |
| GB202002503D0 (en) | Disclosure |